A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection
Latest Information Update: 19 Dec 2022
At a glance
- Drugs Grazoprevir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms C-SPIRIT
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 13 Apr 2014 Final results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
- 13 Apr 2014 Status changed from active, no longer recruiting to completed as reported at the 49th Annual Meeting of the European Association for the Study of the Liver.
- 01 Oct 2013 Results will be presented at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD) according to a Merck media release.